MSA |
in vitro
|
HUVEC |
reduce MMP-2, apoptosis |
[9,30] |
|
in vitro
|
human breast cancer cells, MDA-MB-468 and MCF-7 |
reduce VEGF |
[8] |
|
in vitro
|
human prostate cancer cells, DU145 |
reduce VEGF |
[8] |
|
mice |
human prostate cancer cells, DU145 |
reduce tumor growth and angiogenesis |
[31] |
|
rat |
rat prostate cancer cells, PAIII |
reduce HIF-1α, and VEGF, reduce metastatic lung foci |
[32] |
|
in vitro
|
human fibrosarcoma cell, HT1080 |
inhibit cell invasion, inhibit MMP-2 activation, reduce MT1-MMP and increase TIMP-2 |
[9] |
|
mice |
Lewis lung carcinoma cell |
reduce lung metastasis, reduce plasma uPAand PAI-1 |
[33] |
|
in vitro
|
human clear cell renal cell carcinoma, RC2 |
reduce HIF-1α, and VEGF |
[34] |
|
in vitro
|
human head and neck squamous cell carcinoma, FaDu |
reduce HIF-1α, and VEGF, increase prolyl hroxylases |
[35] |
MSC |
in vitro
|
murine breast cancer cells, TM6 |
inhibit migration |
[36] |
|
rat |
carcinogen-induced breast cancer |
reduce angiogenesis |
[37] |
|
mice |
human breast cancer cells, MCF-7 |
reduce angiogenesis |
[38] |
|
mice |
human colon cancer cells, HCT-8, HT-29 and GEO |
reduce angiogenesis |
[39,40] |
|
mice |
human small cell lung cancer, H69 |
reduce microvessel density, increase vascular maturation |
[41] |
|
mice |
human nonsmall epithelial lung carcinimo, A549 |
increase vascular maturation |
[41] |
|
mice |
human head and neck squamous cell carcinoma, FaDu |
reduce COX-2, iNOS, HIF-1α, and VEGF, reduce microvessel density, increase vascular maturation, drug delivery and distribution |
[35,42,43] |
|
mice |
human head and neck squamous cell carcinoma, A253 |
reduce microvessel density, increase vascular maturation, drug delivery and distribution |
[41] |
SeM |
mice |
murine breast cancer cells, 4T1.2 |
most protection against metastasis |
[44] |
|
mice |
melanoma |
reduce lung metastasis |
[45] |
MeCN |
in vitro
|
HUVEC |
reduce MMP-2 |
[9] |
methylselenol |
in vitro
|
human fibrosarcoma cell, HT1080 |
reduce cell migration and invasion, decrease expression and activity of MMP-2 and MMP-9, increase TIMP1 and TIMP2 |
[46] |
selenite |
in vitro
|
HUVEC |
apoptosis |
[30] |
|
in vitro
|
mammaery endothelial cells |
reduce VEGF |
[47] |
|
rat |
carcinogen-induced breast cancer |
inhibit VEGF, reduce angiogenesis |
[37] |
|
in vitro
|
human fibrosarcoma cell, HT1080 |
reduce cell migration, reduce cell-ECM attachment, reduce MMP-2, MMP-9 and uPA, increase TIMP-1 |
[48] |
|
mice |
murine melanoma cell, B16BL6 |
reduce lung metastasis |
[49] |
|
mice |
murine melanoma cell, B16F10 |
reduce lung metastasis |
[50] |
|
in vitro
|
murine melanoma cell, B16F10 |
inhibit cell migration decrease HIF-1α, VEGF, and IL-18 |
[51] |
|
rat |
carcinogen-indeced liver cancer |
reduce angiogenesis, inhibit angiogenic factors |
[41] |
|
in vitro
|
human astrocytoma cell, IPSB-18 |
reduce MMPs amd EGFR, increase MMP inhibitors |
[52] |
selenate |
in vitro
|
human breast cancer cells, MDA-MB-231 and MCF-7 |
enhance epithelial tight junction, inhibit motility and trans-endothelial invasion |
[53] |
Se-enriched garlic |
rat |
carcinogen-induced breast cancer |
inhibit VEGF, reduce angiogenesis |
[37] |
high Se isolated soy proteins |
mice |
murine melanoma cell, B16BL6 |
reduce lung metastasis |
[54] |
Se-enriched malt |
rat |
carcinogen-indeced liver cancer |
reduce angiogenesis, inhibit angiogenic factors |
[41,55] |